Interplay between oncolytic measles virus, macrophages and cancer cells induces a proinflammatory tumor microenvironment

References

• Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17(8):475–14. doi:10.1038/nrc.2017.42.
   PubMed Web of Science ®Google Scholar
• Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, Opitz I, Scherpereel A, Reck M. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up☆. Ann Of Oncol. 2022;33(2):129–142. doi:10.1016/j.annonc.2021.11.005.
   PubMed Web of Science ®Google Scholar
• Govindan R, Aggarwal C, Antonia SJ, Davies M, Dubinett SM, Ferris A, Forde PM, Garon EB, Goldberg SB, Hassan R. et al. Society for Immunotherapy of cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. J Immunother Cancer. 2022;10(5):e003956. doi:10.1136/jitc-2021-003956.
   PubMed Web of Science ®Google Scholar
• Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet. 2021;397(10272):375–386. doi:10.1016/S0140-6736(20)32714-8.
   PubMed Web of Science ®Google Scholar
• Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy. Science. 2018;362(6411):eaar3593. doi:10.1126/science.aar3593.
   PubMed Web of Science ®Google Scholar
• Minnema-Luiting J, Vroman H, Aerts J, Cornelissen R. Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma. Int J Mol Sci. 2018;19(4):1041. doi:10.3390/ijms19041041.
   PubMed Web of Science ®Google Scholar
• Marcq E, Siozopoulou V, De Waele J, van Audenaerde J, Zwaenepoel K, Santermans E, Hens N, Pauwels P, van Meerbeeck JP, Smits ELJ. Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma. OncoImmunology. 2017;6(1):e1261241. doi:10.1080/2162402X.2016.1261241.
   PubMed Web of Science ®Google Scholar
• Klampatsa A, O’Brien SM, Thompson JC, Rao AS, Stadanlick JE, Martinez MC, Liousia M, Cantu E, Cengel K, Moon EK. et al. Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes. OncoImmunology. 2019;8(9):e1638211. doi:10.1080/2162402X.2019.1638211.
   PubMed Web of Science ®Google Scholar
• Circulating and tumor‐infiltrating myeloid cells predict survival in human pleural mesothelioma - Burt - 2011 - Cancer - Wiley Online Library; accessed 2023 Oct 11]. https://acsjournals-onlinelibrary-wiley-com.proxy.insermbiblio.inist.fr/doi/10.1002/cncr.26143.
   Google Scholar
• Schinwald A, Donaldson K. Use of back-scatter electron signals to visualise cell/nanowires interactions in vitro and in vivo; frustrated phagocytosis of long fibres in macrophages and compartmentalisation in mesothelial cells in vivo. Part Fibre Toxicol. 2012;9(1):1–14. doi:10.1186/1743-8977-9-34.
   PubMed Web of Science ®Google Scholar
• Dostert C, Pétrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through nalp3 inflammasome sensing of asbestos and silica. Science. 2008;320(5876):674–677. doi:10.1126/science.1156995.
   PubMed Web of Science ®Google Scholar
• Chéné A-L, d’Almeida S, Blondy T, Tabiasco J, Deshayes S, Fonteneau J-F, Cellerin L, Delneste Y, Grégoire M, Blanquart C. Pleural effusions from patients with mesothelioma induce recruitment of monocytes and their differentiation into M2 macrophages. J Thorac Oncol: Off Publ Of The Int Assoc For The Study Of Lung Cancer. 2016;11(10):1765–1773. doi:10.1016/j.jtho.2016.06.022.
   Google Scholar
• Blondy T, d’Almeida SM, Briolay T, Tabiasco J, Meiller C, Chéné A-L, Cellerin L, Deshayes S, Delneste Y, Fonteneau J-F. et al. Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma. J Immunother Cancer. 2020;8(1):e000182. doi:10.1136/jitc-2019-000182.
   PubMed Web of Science ®Google Scholar
• Shek D, Gloss B, Lai J, Ma L, Zhang HE, Carlino MS, Mahajan H, Nagrial A, Gao B, Read SA. et al. Identification and characterisation of infiltrating immune cells in malignant pleural mesothelioma using spatial transcriptomics. Methods And Protocol. 2023;6(2):35. doi:10.3390/mps6020035.
   PubMedGoogle Scholar
• Bejarano L, Mjc J, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11(4):933–959. doi:10.1158/2159-8290.CD-20-1808.
   PubMed Web of Science ®Google Scholar
• Wang N, Liang H, Zen K. Molecular Mechanisms That Influence the Macrophage M1–M2 Polarization Balance. Front Immunol. 2014;5. doi:10.3389/fimmu.2014.00614.
   Web of Science ®Google Scholar
• Wu L, Kohno M, Murakami J, Zia A, Allen J, Yun H, Chan M, Baciu C, Liu M, Serre-Beinier V. et al. Defining and targeting tumor-associated macrophages in malignant mesothelioma. Proc Natl Acad Sci U S A. 2023;120(9):e2210836120. doi:10.1073/pnas.2210836120.
   PubMed Web of Science ®Google Scholar
• Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20(3):160–177. doi:10.1038/s41571-022-00719-w.
   PubMed Web of Science ®Google Scholar
• Achard C, Surendran A, Wedge ME, Ungerechts G, Bell J, Ilkow CS. Lighting a fire in the tumor microenvironment using oncolytic immunotherapy. EBioMedicine. 2018;31:17–24. doi:10.1016/j.ebiom.2018.04.020.
   PubMed Web of Science ®Google Scholar
• Msaouel P, Opyrchal M, Dispenzieri A, Peng KW, Federspiel MJ, Russell SJ, Galanis E. Clinical trials with oncolytic measles virus: Current status and future prospects. Curr Cancer Drug Targets. 2018;18(2):177–187. doi:10.2174/1568009617666170222125035.
   PubMed Web of Science ®Google Scholar
• Gauvrit A, Brandler S, Sapede-Peroz C, Boisgerault N, Tangy F, Gregoire M. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res. 2008;68(12):4882–4892. doi:10.1158/0008-5472.CAN-07-6265.
   PubMed Web of Science ®Google Scholar
• Donnelly OG, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K, Peach H, Phillips RM, Bond J, Pandha H. et al. Measles virus causes immunogenic cell death in human melanoma. Gene Ther. 2011;20(1):7–15. doi:10.1038/gt.2011.205.
   PubMed Web of Science ®Google Scholar
• Guillerme JB, Boisgerault N, Roulois D, Menager J, Combredet C, Tangy F, Fonteneau JF, Gregoire M. Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. Clin Cancer Res. 2013;19(5):1147–1158. doi:10.1158/1078-0432.CCR-12-2733.
   PubMed Web of Science ®Google Scholar
• Achard C, Guillerme J-B, Bruni D, Boisgerault N, Combredet C, Tangy F, Jouvenet N, Grégoire M, Fonteneau J-F. Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells. Oncoimmunology. 2017;6(1):e1261240. doi:10.1080/2162402x.2016.1261240.
   PubMed Web of Science ®Google Scholar
• Achard C, Boisgerault N, Delaunay T, Roulois D, Nedellec S, Royer P-J, Pain M, Combredet C, Mesel-Lemoine M, Cellerin L. et al. Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response. Oncotarget. 2015;6(42):44892–44904. doi:10.18632/oncotarget.6285.
   PubMedGoogle Scholar
• Delaunay T, Achard C, Boisgerault N, Grard M, Petithomme T, Chatelain C, Dutoit S, Blanquart C, Royer P-J, Minvielle S. et al. Frequent homozygous deletions of type I Interferon genes in pleural mesothelioma confer sensitivity to oncolytic measles virus. J Thorac Oncol: Off Publ Of The Int Assoc For The Study Of Lung Cancer. 2020;15(5):827–842. doi:10.1016/j.jtho.2019.12.128.
   Google Scholar
• Gueugnon F, Leclercq S, Blanquart C, Sagan C, Cellerin L, Padieu M, Perigaud C, Scherpereel A, Gregoire M. Identification of novel markers for the diagnosis of malignant pleural mesothelioma. The Am J Pathol. 2011;178(3):1033–1042. doi:10.1016/j.ajpath.2010.12.014.
   PubMed Web of Science ®Google Scholar
• Combredet C, Labrousse V, Mollet L, Lorin C, Delebecque F, Hurtrel B, McClure H, Feinberg MB, Brahic M, Tangy F. A molecularly cloned schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol. 2003;77(21):11546–11554. doi:10.1128/JVI.77.21.11546-11554.2003.
   PubMed Web of Science ®Google Scholar
• Monaco G, Chen H, Poidinger M, Chen J, de Magalhães Jp, Larbi A, de Magalhães JP. flowAI: automatic and interactive anomaly discerning tools for flow cytometry data. Bioinformatics. 2016;32(16):2473–2480. doi:10.1093/bioinformatics/btw191.
   PubMed Web of Science ®Google Scholar
• Van Gassen S, Callebaut B, Van Helden MJ, Lambrecht BN, Demeester P, Dhaene T, Saeys Y. FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A. 2015;87(7):636–645. doi:10.1002/cyto.a.22625.
   PubMedGoogle Scholar
• McInnes L, Healy J, Saul N, Großberger L. UMAP: Uniform Manifold Approximation and Projection. J Open Source Softw. 2018;3(29):861. doi:10.21105/joss.00861.
   Google Scholar
• Belkina AC, Ciccolella CO, Anno R, Halpert R, Spidlen J, Snyder-Cappione JE. Automated optimized parameters for T-distributed stochastic neighbor embedding improve visualization and analysis of large datasets. Nat Commun. 2019;10(1):5415. doi:10.1038/s41467-019-13055-y.
   PubMed Web of Science ®Google Scholar
• Pearson KL. LIII. on lines and planes of closest fit to systems of points in space. The Lond, Edinburgh, And Dublin Phil Mag And J Sci. 1901;2(11):559–572. doi:10.1080/14786440109462720.
   Google Scholar
• Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B. et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676–682. doi:10.1038/nmeth.2019.
   PubMed Web of Science ®Google Scholar
• Charpentier E, Cornec M, Dumont S, Meistermann D, Bordron P, David L, Redon R, Bonnaud S, Bihouée A. 3’ RNA sequencing for robust and low-cost gene expression profiling. [2021 Jan 28]. doi:10.21203/rs.3.pex-1336/v1.
   Google Scholar
• Taverna F, Goveia J, Karakach TK, Khan S, Rohlenova K, Treps L, Subramanian A, Schoonjans L, Dewerchin M, Eelen G. et al. BIOMEX: an interactive workflow for (single cell) omics data interpretation and visualization. Nucleic Acids Res. 2020;48(W1):W385–W394. doi:10.1093/nar/gkaa332.
   PubMed Web of Science ®Google Scholar
• Ulgen E, Ozisik O, Ou S. pathfindR: An R Package for Comprehensive Identification of Enriched Pathways in Omics Data Through Active Subnetworks. Front Genet. 2019;10:10. doi:10.3389/fgene.2019.00858.
   PubMed Web of Science ®Google Scholar
• Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32(1):513–545. doi:10.1146/annurev-immunol-032713-120231.
   PubMed Web of Science ®Google Scholar
• Lievense LA, Cornelissen R, Bezemer K, Kaijen-Lambers MEH, Jpjj H, Jgjv A. Pleural effusion of patients with malignant mesothelioma induces macrophage-mediated T cell suppression. J Thorac Oncol. 2016;11(10):1755–1764. doi:10.1016/j.jtho.2016.06.021.
   PubMed Web of Science ®Google Scholar
• Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000;6(7):821–825. doi:10.1038/77558.
   PubMed Web of Science ®Google Scholar
• Grard M, Chatelain C, Delaunay T, Pons-Tostivint E, Bennouna J, Fonteneau JF. Homozygous Co-Deletion of Type I Interferons and CDKN2A genes in thoracic cancers: Potential consequences for therapy. Front Oncol. 2021;11:695770. doi:10.3389/fonc.2021.695770.
   PubMed Web of Science ®Google Scholar
• Barriga FM, Tsanov KM, Ho Y-J, Sohail N, Zhang A, Baslan T, Wuest AN, Del Priore I, Meškauskaitė B, Livshits G. et al. MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis. Nat Cancer. 2022;3(11):1367–1385. doi:10.1038/s43018-022-00443-5.
   PubMedGoogle Scholar
• Peng Y, Chen Y, Song M, Zhang X, Li P, Yu X, Huang Y, Zhang N, Ji L, Xia L. et al. Co-occurrence of CDKN2A/B and IFN-I homozygous deletions correlates with an immunosuppressive phenotype and poor prognosis in lung adenocarcinoma. Mol Oncol. 2022;16(8):1746–1760. doi:10.1002/1878-0261.13206.
   PubMed Web of Science ®Google Scholar
• Tan DQ, Zhang L, Ohba K, Ye M, Ichiyama K, Yamamoto N. Macrophage response to oncolytic paramyxoviruses potentiates virus-mediated tumor cell killing. Eur J Immunol. 2016;46(4):919–928. doi:10.1002/eji.201545915.
   PubMed Web of Science ®Google Scholar
• Karin N. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond. Front Immunol. 2020;11:11. doi:10.3389/fimmu.2020.00976.
   PubMed Web of Science ®Google Scholar
• Veinalde R, Pidelaserra-Martí G, Moulin C, Tan CL, Schäfer TE, Kang N, Ball CR, Leichsenring J, Stenzinger A, Kaderali L. et al. Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model. Front Immunol. 2023;13. doi:10.3389/fimmu.2022.1096162.
   PubMed Web of Science ®Google Scholar
• Backhaus PS, Veinalde R, Hartmann L, Dunder JE, Jeworowski LM, Albert J, Hoyler B, Poth T, Jager D, Ungerechts G. et al. Immunological effects and viral gene expression determine the efficacy of oncolytic measles vaccines encoding IL-12 or IL-15 Agonists. Viruses. 2019;11(10):914. doi:10.3390/v11100914.
   PubMed Web of Science ®Google Scholar
• Busch E, Kubon KD, Mayer JKM, Pidelaserra-Martí G, Albert J, Hoyler B, Heidbuechel JPW, Stephenson KB, Lichty BD, Osen W. et al. Measles Vaccines Designed for enhanced CD8+ T Cell Activation. Viruses. 2020;12(2):242. doi:10.3390/v12020242.
   PubMed Web of Science ®Google Scholar
• Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves Anti-PD-1 Immunotherapy. Cell. 2018;174(4):1031–1032. doi:10.1016/j.cell.2018.07.035.
   PubMed Web of Science ®Google Scholar